Holen Sie sich die Stockscreener-App
1.13
0.88%
-0.01
Handel nachbörslich:
1.15
0.02
+1.77%
Lucid Diagnostics Inc Aktie (LUCD) Neueste Nachrichten
Q3 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Aug Action: Whats the MACD signal for Lucid Diagnostics Inc2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
LUCD PE Ratio & Valuation, Is LUCD Overvalued - Intellectia AI
Lucid Diagnostics Inc. (LUCD) stock price, news, quote and history - Yahoo Finance UK
PAVmed appoints Joseph Virgilio as medical device chief By Investing.com - Investing.com Canada
Duke-licensed esophageal imaging joins PAVmed device relaunch - stocktitan.net
Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Update - marketbeat.com
Dow Update: Can Lucid Diagnostics Inc be recession proof2026 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
Lucid Diagnostics’ Earnings Call: Momentum Amid Cash Strain - The Globe and Mail
LUCD: BTIG Reiterates Buy Rating with $2.50 Price Target | LUCD Stock News - GuruFocus
Profit Review: Whats the MACD signal for Lucid Diagnostics Inc2026 Trends & Scalable Portfolio Growth Ideas - baoquankhu1.vn
PAVmed Reports 2025 Financial Results, Strengthens Capital Structure, and Expands Medical Device Portfolio Under New Leadership - Minichart
BTIG reiterates Lucid Diagnostics stock rating on Q4 beat By Investing.com - Investing.com South Africa
Lucid Diagnostics (NASDAQ:LUCD) Earns Buy Rating from BTIG Research - marketbeat.com
PAVmed (NASDAQ: PAVM) overhauls capital structure and reports 2025 results - stocktitan.net
Lucid Diagnostics (LUCD) Earnings Transcript - AOL.com
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - MarketScreener
Cancer screening test wins VA access for 9 million veterans - stocktitan.net
BTIG reiterates Lucid Diagnostics stock rating on Q4 beat - Investing.com
Lucid Diagnostics Inc. (LUCD) reports Q4 loss, beats revenue estimates - MSN
Lucid Diagnostics non-GAAP adjusted loss hits USD 12.6M in Q4 2025 - Medical Buyer
Lucid Diagnostics (NASDAQ:LUCD) Rating Increased to Hold at Wall Street Zen - marketbeat.com
Valuation Update: What is the long term forecast for Lucid Diagnostics Inc stockQuarterly Trade Review & Stepwise Trade Execution Plans - baoquankhu1.vn
PAVmed (PAVM) outlines going concern risk, Nasdaq compliance and growth plans - stocktitan.net
Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2025 Earnings Call Transcript - Insider Monkey
[EFFECT] Lucid Diagnostics Inc. SEC Filing - Stock Titan
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - StreetInsider
Lucid Diagnostics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-03-27 - Seeking Alpha
Lucid Diagnostics reports Q4 revenue of $1.5M, VA contract By Investing.com - Investing.com South Africa
Lucid Diagnostics signals expanded VA market access and 29% sequential test volume growth while targeting Medicare and commercial payer wins - msn.com
Lucid Diagnostics Reports 2025 Financial Results, Expands EsoGuard Access with VA Contract and Positive Real-World Data - Minichart
Lucid Diagnostics (NASDAQ: LUCD) launches ATM program to sell up to $25M - Stock Titan
Lucid Diagnostics Inc (LUCD) Q4 2025 Earnings Call Highlights: Strong Test Volume Growth and ... By GuruFocus - Investing.com Canada
Lucid Diagnostics Reports Q4 2025 Results, Highlights VA Contract - TipRanks
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Australia
The Dixie Group Q4 2025 Financial Review - AlphaStreet
Lucid Diagnostics Q4 2025 Earnings Call Transcript - MarketBeat
Lucid Diagnostics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham & Company LLC Reiterates Buy Rating for Lucid Diagnostics (NASDAQ:LUCD) - MarketBeat
Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
LUCD: Test volume and revenue surged, with Medicare and VA poised to drive future growth - TradingView
Lucid Diagnostics Provides Business Update and Reports Fourth Qu - GuruFocus
Lucid Diagnostics Inc. (LUCD) Reports Q4 Earnings - AlphaStreet
LUCD: Strong Q4 growth, VA contract, and imminent Medicare coverage position for accelerated revenue - TradingView
Lucid Diagnostics Q4 Earnings Call Highlights - marketbeat.com
Earnings call transcript: Lucid Diagnostics Q4 2025 sees stock rise despite EPS miss By Investing.com - Investing.com South Africa
Earnings call transcript: Lucid Diagnostics Q4 2025 sees stock rise despite EPS miss - Investing.com
Lucid Diagnostics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Canaccord reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com India
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):